Report Id: MDHTM0222
Hormonal Therapy Market Size by Type (Anti-estrogens, Aromatase Inhibitors, Anti-androgens, Gonadotropin Releasing Hormone (GnRH) and Others), By Application (Breast Cancer, Prostate Cancer, Ovarian Cancer and Others), By Route of Administration (Oral, Subcutaneous and Intramuscular), By Region (North America, Europe, Asia-Pacific, Rest of the World), Market Analysis Report, Forecast 2023-2028
The Hormonal Therapy Market is expected to be around US$ 52 Billion by 2028 at a CAGR of 5% in the given forecast period.
COVID-19 Impact Analysis Report
"Get Latest Updated Reports as per the COVID-19 Impact"
Infopedia: Access Our All Reports Online at Affordable Price
CLICK HEREMARKET SNAPSHOT
Major Players
- AstraZeneca
- Pfizer
- Novartis
- Sanofi
- Takeda
Study period:
Fastest Growing Market:
2023-2028
APAC
Base Year:
Largest Market:
2022
North America
CAGR:
5
REPORT DESCRIPTION
The Hormonal Therapy Market is expected to be around US$ 52 Billion by 2028 at a CAGR of 5% in the given forecast period.
Rise in incidence and prevalence of cancer such as breast cancer and prostate cancer is projected to catalyze the hormonal therapy market. Also, the escalating in demand for newer agents which aim to avoid resistance and combination therapies is leading to boost the growth of hormonal therapy market. Moreover, the rise in government and private organization support to improve the awareness about cancer treatment is anticipated to accelerate the market. For example, the World Health Organization promotes breast cancer regulate within the circumstance of comprehensive national cancer control programs. In addition to this, in spite of high cost involved in research and development, pharmaceutical companies are showing high interest in this field. This is likely to propel growth of the hormonal therapy market.
The global Hormonal Therapy market is segregated on the basis of Type as Anti-estrogens, Aromatase Inhibitors, Anti-androgens, Gonadotropin Releasing Hormone (GnRH) and Others. Based on Application the global Hormonal Therapy market is segmented in Breast Cancer, Prostate Cancer, Ovarian Cancer and Others. Based on Route of Administration the global Hormonal Therapy market is segmented in Oral, Subcutaneous and Intramuscular.
The global Hormonal Therapy market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Hormonal Therapy market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
AstraZeneca, Novartis, Pfizer, Sanofi, Takeda, Roche, Amgen, Samyang Biopharmaceuticals, Tolmar, Bluebird Bio, Bristol-Myers Squibb, Exelixis, Guardant Health, Illumina, and others are among the major players in the global Hormonal Therapy market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Hormonal Therapy Market has been segmented as below:
Hormonal Therapy Market, By Type
- Anti-estrogens
- Aromatase Inhibitors
- Anti-androgens
- Gonadotropin Releasing Hormone (GnRH)
- Others
Hormonal Therapy Market, By Application
- Breast Cancer
- Prostate Cancer
- Ovarian Cancer
- Others
Hormonal Therapy Market, By Route of Administration
- Oral
- Subcutaneous
- Intramuscular
Hormonal Therapy Market, By Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Hormonal Therapy Market, By Company
- AstraZeneca
- Novartis
- Pfizer
- Sanofi
- Takeda
- Roche
- Amgen
- Samyang Biopharmaceuticals
- Tolmar
- Bluebird Bio
- Bristol-Myers Squibb
- Exelixis
- Guardant Health
- Illumina
The report covers:
- Global Hormonal Therapy market sizes from 2021 to 2028, along with CAGR for 2023-2028
- Market size comparison for 2022 vs 2028, with actual data for 2022, estimates for 2023 and forecast from 2024 to 2028
- Global Hormonal Therapy market trends, covering comprehensive range of consumer trends & manufacturer trends
- Value chain analysis covering participants from raw material suppliers to the downstream buyer in the global Hormonal Therapy market
- Major market opportunities and challenges in forecast timeframe to be focused
- Competitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic management
- Comprehensive company profiles of the key industry players
Report Scope:
The global Hormonal Therapy market report scope includes detailed study covering underlying factors influencing the industry trends. The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Hormonal Therapy market share. Major industry players with significant revenue share include AstraZeneca, Novartis, Pfizer, Sanofi, Takeda, Roche, Amgen, Samyang Biopharmaceuticals, Tolmar, Bluebird Bio, Bristol-Myers Squibb, Exelixis, Guardant Health, Illumina, and others.
Reasons to Buy this Report:
- Gain detailed insights on the Hormonal Therapy industry trends
- Find complete analysis on the market status
- Identify the Hormonal Therapy market opportunities and growth segments
- Analyse competitive dynamics by evaluating business segments & product portfolios
- Facilitate strategy planning and industry dynamics to enhance decision making
Customization
Customized report as per the requirement can be offered with appropriate recommendations
Below are our new reports:
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Market Research Process
2.3. Research Data Analysis
2.3.1.1. Secondary Research
2.3.1.2. Primary Research
2.3.1.3. Models for Estimation
2.4. Market Size Estimation
2.4.1. Bottom-Up Approach- Segmental Market Analysis
2.4.2. Top-Down Approach- Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1. Introduction
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. Porter's Five Force Analysis
5. Hormonal Therapy Market, By Type
5.1. Introduction
5.2. Anti-estrogens
5.2.1. Market Overview
5.2.2. Market Size and Forecast
5.3. Aromatase Inhibitors
5.3.1. Market Overview
5.3.2. Market Size and Forecast
5.4. Anti-androgens
5.4.1. Market Overview
5.4.2. Market Size and Forecast
5.5. Gonadotropin Releasing Hormone (GnRH)
5.5.1. Market Overview
5.5.2. Market Size and Forecast
5.6. Others
5.6.1. Market Overview
5.6.2. Market Size and Forecast
6. Hormonal Therapy Market, By Application
6.1. Introduction
6.2. Breast Cancer
6.2.1. Market Overview
6.2.2. Market Size and Forecast
6.3. Prostate Cancer
6.3.1. Market Overview
6.3.2. Market Size and Forecast
6.4. Ovarian Cancer
6.4.1. Market Overview
6.4.2. Market Size and Forecast
6.5. Others
6.5.1. Market Overview
6.5.2. Market Size and Forecast
7. Hormonal Therapy Market, By Route of Administration
7.1. Introduction
7.2. Oral
7.2.1. Market Overview
7.2.2. Market Size and Forecast
7.3. Subcutaneous
7.3.1. Market Overview
7.3.2. Market Size and Forecast
7.4. Intramuscular
7.4.1. Market Overview
7.4.2. Market Size and Forecast
8. Hormonal Therapy Market, By Geography
8.1. Introduction
8.2. North America
8.2.1. North America Hormonal Therapy, By Type
8.2.2. North America Hormonal Therapy, By Application
8.2.3. North America Hormonal Therapy, By Route of Administration
8.3. Europe
8.3.1. Europe Hormonal Therapy, By Type
8.3.2. Europe Hormonal Therapy, By Application
8.3.3. Europe Hormonal Therapy, By Route of Administration
8.4. Asia-Pacific
8.4.1. Asia-Pacific Hormonal Therapy, By Type
8.4.2. Asia-Pacific Hormonal Therapy, By Application
8.4.3. Asia-Pacific Hormonal Therapy, By Route of Administration
8.5. Rest of the World
8.5.1. Rest of the World Hormonal Therapy, By Type
8.5.2. Rest of the World Hormonal Therapy, By Application
8.5.3. Rest of the World Hormonal Therapy, By Route of Administration
9. Competitive Insights
9.1. Key Insights
9.2. Company Market Share Analysis
9.3. Strategic Outlook
9.3.1. Mergers & Acquisitions
9.3.2. New Product Developments
9.3.3. Portfolio/Production Capacity Expansions
9.3.4. Joint Ventures, Collaborations, Partnerships & Agreements
9.3.5. Others
10. Company Profiles
10.1. AstraZeneca
10.1.1. Company Overview
10.1.2. Product/Service Landscape
10.1.3. Financial Overview
10.1.4. Recent Developments
10.2. Novartis
10.2.1. Company Overview
10.2.2. Product/Service Landscape
10.2.3. Financial Overview
10.2.4. Recent Developments
10.3. Pfizer
10.3.1. Company Overview
10.3.2. Product/Service Landscape
10.3.3. Financial Overview
10.3.4. Recent Developments
10.4. Sanofi
10.4.1. Company Overview
10.4.2. Product/Service Landscape
10.4.3. Financial Overview
10.4.4. Recent Developments
10.5. Takeda
10.5.1. Company Overview
10.5.2. Product/Service Landscape
10.5.3. Financial Overview
10.5.4. Recent Developments
10.6. Roche
10.6.1. Company Overview
10.6.2. Product/Service Landscape
10.6.3. Financial Overview
10.6.4. Recent Developments
10.7. Amgen
10.7.1. Company Overview
10.7.2. Product/Service Landscape
10.7.3. Financial Overview
10.7.4. Recent Developments
10.8. Samyang Biopharmaceuticals
10.8.1. Company Overview
10.8.2. Product/Service Landscape
10.8.3. Financial Overview
10.8.4. Recent Developments
10.9. Tolmar
10.9.1. Company Overview
10.9.2. Product/Service Landscape
10.9.3. Financial Overview
10.9.4. Recent Developments
10.10. Bluebird Bio
10.10.1. Company Overview
10.10.2. Product/Service Landscape
10.10.3. Financial Overview
10.10.4. Recent Developments
10.11. Bristol-Myers Squibb
10.11.1. Company Overview
10.11.2. Product/Service Landscape
10.11.3. Financial Overview
10.11.4. Recent Developments
10.12. Exelixis
10.12.1. Company Overview
10.12.2. Product/Service Landscape
10.12.3. Financial Overview
10.12.4. Recent Developments
10.13. Guardant Health
10.13.1. Company Overview
10.13.2. Product/Service Landscape
10.13.3. Financial Overview
10.13.4. Recent Developments
10.14. Illumina
10.14.1. Company Overview
10.14.2. Product/Service Landscape
10.14.3. Financial Overview
10.14.4. Recent Developments
The Hormonal Therapy Market has been segmented as below:
Hormonal Therapy Market, By Type
- Anti-estrogens
- Aromatase Inhibitors
- Anti-androgens
- Gonadotropin Releasing Hormone (GnRH)
- Others
Hormonal Therapy Market, By Application
- Breast Cancer
- Prostate Cancer
- Ovarian Cancer
- Others
Hormonal Therapy Market, By Route of Administration
- Oral
- Subcutaneous
- Intramuscular
Hormonal Therapy Market, By Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Hormonal Therapy Market, By Company
- AstraZeneca
- Novartis
- Pfizer
- Sanofi
- Takeda
- Roche
- Amgen
- Samyang Biopharmaceuticals
- Tolmar
- Bluebird Bio
- Bristol-Myers Squibb
- Exelixis
- Guardant Health
- Illumina
Got a question? We've got answers. If you have some other questions, see our support center.
What is the predicted growth rate of Hormonal Therapy Market?
The market is expected to grow at a CAGR of 5% during the study period (2023-2028)
How big is the Hormonal Therapy Market value?
The Hormonal Therapy Market is expected to be around US$ 52 Billion by 2028
What is the segment’s covered for the Hormonal Therapy Market?
The segment included in Hormonal Therapy Market is Type, Application, Route of Administration and region.
Who are the major key vendors in the Hormonal Therapy Market?
Some key players operating in Hormonal Therapy Market include AstraZeneca, Novartis, Pfizer, Sanofi, Takeda, Roche, Amgen, Samyang Biopharmaceuticals, Tolmar, Bluebird Bio, Bristol-Myers Squibb
What are the different forms of the report available?
We can offer several formats of the market research reports including,
• PDF
• PPT
• Spreadsheet/ Workbook
© 2020 COPYRIGHT : MARKET RESEARCH ENGINE